CD58 Antigens (LFA-3)

Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.

Also Known As:

Networked: 121 relevant articles (0 outcomes, 9 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Schlom, Jeffrey: 8 articles (10/2010 - 10/2002)
2.	Hodge, James W: 5 articles (05/2008 - 10/2002)
3.	Tsang, Kwong-Yok: 3 articles (10/2010 - 05/2008)
4.	Palena, Claudia: 3 articles (10/2010 - 05/2008)
5.	Poole, Diane J: 3 articles (05/2008 - 05/2003)
6.	Aarts, Wilhelmina M: 3 articles (11/2003 - 10/2002)
7.	Litzinger, Mary T: 2 articles (10/2010 - 06/2009)
8.	Foon, Kenneth A: 2 articles (10/2010 - 06/2009)
9.	Kaufman, Howard L: 2 articles (06/2006 - 02/2006)
10.	Li, Ya-Fei: 1 article (08/2015)

Related Diseases

1.	Neoplasms (Cancer) 03/01/1999 - "These studies demonstrate that expression of LFA-3 via a poxvirus vector can be used to induce anti-tumor immunity." 03/01/1999 - "To determine the effect of LFA-3 expression on the immunogenicity of tumor cells, we constructed a recombinant vaccinia virus containing the murine LFA-3 gene (designated rV-LFA-3). " 03/01/1999 - "Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus." 04/01/1998 - "From a practical point of view, our data demonstrate that the level of LFA-3 expressed on tumors critically affects cytokine production by specific CTL and thus the efficiency of specific immune reactions mediated by these cells." 12/20/1995 - "LFA-3 was absent from 8% (4/49) of the primary tumors and reduced (e.g., < or = 50% positive cells) in 33% (16/49). "
2.	Melanoma (Melanoma, Malignant) 04/01/1998 - "Our results indicate that increasing LFA-3 density on melanoma cells variably affects their lysis susceptibility, but systematically and considerably enhances cytokine production by melanoma-specific cytotoxic T lymphocyte (CTL) clones. " 04/01/1998 - "To this end we analyzed the influence of LFA-3 density on melanoma cells on lysis and cytokine production (TNF, IL-2, IFN-gamma) by T cells following activation by various amounts of antigenic peptides. " 09/01/1994 - "For this last type of clone, we further showed that defective IL-2 induction resulted from an LFA-3 defect of some melanoma cells or from distinct yet undefined defects of other melanoma lines. " 08/01/1994 - "The genes for huICAM-1 (a ligand for LFA-1) and huLFA-3 (a ligand for CD2) were transfected singly and in combination into a null mouse melanoma background, and clonal populations of cells that stably express ICAM-1 and/or LFA-3 were derived. " 05/28/1993 - "These data show that expression and release of LFA-3 and ICAM-1 differ between melanoma cell lines. "
3.	Vaccinia 07/01/1992 - "The recombinant vaccinia-encoded LFA-3 was functional as an adhesion molecule since BL cells acutely infected with Vacc-LFA-3 then acquired the ability to form conjugates with activated T cells in vitro. " 05/15/2008 - "We report here a pilot study of 25 patients treated with a poxviral vaccine regimen consisting of the genes for CEA and MUC-1, along with a triad of costimulatory molecules (TRICOM; composed of B7.1, intercellular adhesion molecule 1, and lymphocyte function-associated antigen 3) engineered into vaccinia (PANVAC-V) as a prime vaccination and into fowlpox (PANVAC-F) as a booster vaccination. " 05/01/2003 - "These mice were vaccinated with recombinant poxviral vectors [recombinant vaccinia, recombinant fowlpox (rF)] encoding the CEA transgene as well as a triad of costimulatory molecules [B7-1, ICAM-1, and LFA-3 (TRICOM)]. " 06/01/2009 - "We previously demonstrated that infection of CLL cells with modified vaccinia Ankara (MVA) expressing the costimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM) increased expression of these costimulatory molecules on the surface of CLL cells and thus augmented their antigen-presenting capability. " 10/15/2002 - "The vaccines used were recombinant vaccinia virus containing the transgenes for CEA and three T-cell costimulatory molecules [B7-1, ICAM-1, and LFA-3, designated recombinant vaccinia (rV)-CEA/TRICOM], with each transgene under the control of individual poxvirus promoters, and a replication-defective avipox virus (fowlpox; rF) containing the same four transgenes (designated rF-CEA/TRICOM). "
4.	Fowlpox 05/15/2008 - "We report here a pilot study of 25 patients treated with a poxviral vaccine regimen consisting of the genes for CEA and MUC-1, along with a triad of costimulatory molecules (TRICOM; composed of B7.1, intercellular adhesion molecule 1, and lymphocyte function-associated antigen 3) engineered into vaccinia (PANVAC-V) as a prime vaccination and into fowlpox (PANVAC-F) as a booster vaccination. " 05/01/2003 - "These mice were vaccinated with recombinant poxviral vectors [recombinant vaccinia, recombinant fowlpox (rF)] encoding the CEA transgene as well as a triad of costimulatory molecules [B7-1, ICAM-1, and LFA-3 (TRICOM)]. " 10/15/2002 - "The vaccines used were recombinant vaccinia virus containing the transgenes for CEA and three T-cell costimulatory molecules [B7-1, ICAM-1, and LFA-3, designated recombinant vaccinia (rV)-CEA/TRICOM], with each transgene under the control of individual poxvirus promoters, and a replication-defective avipox virus (fowlpox; rF) containing the same four transgenes (designated rF-CEA/TRICOM). " 01/01/2006 - "Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM) to these vaccines, we conducted a Phase I study to evaluate the safety and immunogenicity of a novel vaccinia and fowlpox vaccine incorporating the PSA gene sequence and TRICOM. "
5.	Oral Lichen Planus 11/01/1999 - "To assess the importance of LFA-3 in this process, this study used an adaptation of the Stamper-Woodruff lymphocyte adhesion assay to measure the binding of exogenous activated lymphocytes to the T-cell-dominated chronic inflammatory infiltrate of oral lichen planus. " 12/01/1995 - "Expression of lymphocyte function-associated antigen 3 in oral lichen planus." 12/01/1995 - "The expression pattern of lymphocyte function-associated antigen 3 (LFA-3) in the buccal mucosa of oral lichen planus (OLP) patients was compared to that of healthy controls to investigate the possible role of LFA-3 in cell interactions within OLP lesions. " 08/01/1998 - "The results show similar patterns of expression of very late activation antigen-4, lymphocyte function-associated antigen-3 and intercellular adhesion molecule-1, but relatively elevated levels of these antigens in oral lichen planus patients with no hepatitis C virus infection. "

Related Drugs and Biologics

1.	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
2.	Lymphocyte Function-Associated Antigen-1 (LFA-1)
3.	Cell Adhesion Molecules
4.	adhesion receptor
5.	Immunoglobulin G (IgG)
6.	DNA (Deoxyribonucleic Acid)
7.	alefacept (Amevive)
8.	Vaccines
9.	Carbon Monoxide
10.	Luteolin

Related Therapies and Procedures

1.	Ligation
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)